The European Medicines Agencys Pharmacovigilance Risk Assessment Committee also concluded that NAION should be listed as a very rare side effect of semaglutide medications after reviewing clinical trials, post-marketing surveillance, non-clinical data, and published medical literature
The company states that most patients begin with the "Jumpstart" option, which is a 4-month commitment
These reactions are classified as uncommon, meaning they may affect up to 1 in 100 people
SURPASS-2 compared tirzepatide with semaglutide 1 mg in type 2 diabetes, and SUSTAIN 7 compared semaglutide with dulaglutide
[1] [3] If you consistently cannot meet minimum nutritional requirements, schedule a follow-up appointment to discuss whether medication adjustment or nutritional supplementation is warranted
Do not put the vial in checked luggage where temperature extremes are common